RIA of nonpregnant rat uterus extracts showed 0.68 Ϯ 0.08 pmol/g adrenomedullin (ADM) and 3.23 Ϯ 0.08 pmol/g calcitonin gene-related peptide (CGRP). In the pregnant (20 days gestation) uterus, the ADM content was 0.90 Ϯ 0.17 pmol/g, and CGRP could not be detected. ADM messenger RNA was detected at high levels in the uterus, with a 1.8-fold increase in expression in pregnancy. Pharmacologically distinct binding sites for ADM (B max ϭ 21 Ϯ 2 fmol/mg protein, dissociation constant ϭ 80 Ϯ 6 pM), and CGRP (B max ϭ 101 Ϯ 18 fmol/mg protein, dissociation constant ϭ 140 Ϯ 20 pM) were identified in nonpregnant uterus. Competition for 125 I[Tyr 0 ]␣CGRP binding was shown by both ADM and CGRP (8 -37), whereas CGRP and CGRP (8 -37) did not compete for 125 I-ADM-binding sites. The density of the ADM-binding sites was 10 times greater in pregnant uterus (B max ϭ 211 Ϯ 39 fmol/mg protein, P Ͻ 0.01) than nonpregnant uterus. CGRP receptor messenger RNA was identified in both nonpregnant and pregnant uteri. In isolated nonpregnant rat uteri, CGRP and ADM attenuated the contractile response to galanin by 77 Ϯ 10% and 57 Ϯ 10%, respectively. The responses to both CGRP and ADM were abolished by CGRP (8 -37). These results demonstrate, for the first time, the presence of ADM and specific binding sites for both ADM and CGRP in the rat uterus. (Endocrinology 138: 2508 -2514, 1997) A DRENOMEDULLIN (ADM) is a 52-amino acid peptide originally isolated from human phaeochromocytomas (1). It is a member of the calcitonin family of peptides with sequence homology to calcitonin gene-related peptide (CGRP) and islet amyloid polypeptide (IAPP). The distribution and biological effects of ADM and CGRP overlap in many tissues. ADM immunoreactivity (ADM-IR) and messenger RNA (mRNA) have been identified in a number of human and rat tissues, including heart and lung (2-5). CGRP-immunoreactive (CGRP-IR) neurons innervate the majority of tissues, with the capsaicin-sensitive ␣CGRP-containing primary afferent neurones predominating in the cardiovascular system, brain and urinogenital tract but with both ␣CGRP and ␤CGRP-containing neurons present in the gastrointestinal tract (6 -8).
I[Tyr 0 ]␣CGRP binding was shown by both ADM and CGRP (8 -37) , whereas CGRP and CGRP (8 -37) did not compete for 125 I-ADM-binding sites. The density of the ADM-binding sites was 10 times greater in pregnant uterus (B max ϭ 211 Ϯ 39 fmol/mg protein, P Ͻ 0.01) than nonpregnant uterus. CGRP receptor messenger RNA was identified in both nonpregnant and pregnant uteri. In isolated nonpregnant rat uteri, CGRP and ADM attenuated the contractile response to galanin by 77 Ϯ 10% and 57 Ϯ 10%, respectively. The responses to both CGRP and ADM were abolished by CGRP (8 -37) . These results demonstrate, for the first time, the presence of ADM and specific binding sites for both ADM and CGRP in the rat uterus. (Endocrinology 138: 2508 -2514, 1997) A DRENOMEDULLIN (ADM) is a 52-amino acid peptide originally isolated from human phaeochromocytomas (1) . It is a member of the calcitonin family of peptides with sequence homology to calcitonin gene-related peptide (CGRP) and islet amyloid polypeptide (IAPP). The distribution and biological effects of ADM and CGRP overlap in many tissues. ADM immunoreactivity (ADM-IR) and messenger RNA (mRNA) have been identified in a number of human and rat tissues, including heart and lung (2) (3) (4) (5) . CGRP-immunoreactive (CGRP-IR) neurons innervate the majority of tissues, with the capsaicin-sensitive ␣CGRP-containing primary afferent neurones predominating in the cardiovascular system, brain and urinogenital tract but with both ␣CGRP and ␤CGRP-containing neurons present in the gastrointestinal tract (6 -8) .
One of the major biological effects of both CGRP and ADM is their ability to relax smooth muscle. In the guinea pig lung, ADM acts as a potent bronchodilator (9) , and CGRP has been shown to relax guinea pig trachea and rat respiratory tract smooth muscle (10, 11) . ADM and CGRP are potent vasodilators in many species (12) (13) (14) (15) (16) . The specific CGRP receptor subtype 1 (CGRP 1 ) antagonist, CGRP (8 -37) , inhibits the vasodilator response to ADM in the isolated perfused mesenteric vascular bed (17) and in the isolated rat heart (18) , indicating that the effect of ADM in these tissues is via CGRP 1 receptors. However, the systemic hypotensive effect of CGRP, but not that of ADM, is blocked in vivo by CGRP (8 -37) (14, 19) , showing that their systemic effects are mediated by different receptors. Specific binding sites for ADM that do not bind CGRP have been identified in a number of rat tissues (20) , blood vessels (14) , and vascular smooth muscle cells (21) . We have recently cloned a rat ADM receptor (22) that displays a similar pharmacology and mRNA distribution to the binding sites identified in rat tissues (20) . In addition, we have shown that the orphan dog RDC1 receptor, when expressed in COS-7 cells, has the pharmacological characteristics of a CGRP 1 receptor (23) .
CGRP-IR previously has been identified in neurones innervating the female rat urinogenital tract (7) . Capsaicin treatment depletes the majority of CGRP-IR in these tissues, indicating that this immunoreactivity is probably ␣CGRP localized to the primary sensory afferent neurones (7) . Immunocytochemistry of rat uterus has shown that CGRP-IR fibres innervate the mesometrium of the uterine horn, the mesometrial smooth muscle, and vascular smooth muscle and also are located in the myometrium, endometrium, and endocervix of the uterine wall (24) . CGRP has been shown to inhibit spontaneous contractions in the rat and human uterus (25, 26) . Although CGRP and CGRP (8 -37) do not affect basal uterine tension in rats, CGRP elicits dose-dependent relaxation of uterine smooth muscle precontracted with acetylcholine or galanin (24, 27) . CGRP-IR, in the neurons innervating the guinea pig uterus, disappears during late pregnancy (28) . CGRP is expressed not only in sensory neurones but also in spinal motoneurones in the rat and man (29, 30) . In addition to its relaxant effect, CGRP derived from motoneurones also has been proposed to act as an anterograde muscle trophic factor. CGRP has a role in the regulation of acetylcholine receptor gene expression at the neuromuscular junction (31) and has been shown to increase cAMP levels in skeletal muscle (32) .
Because the distributions and functions of CGRP and ADM overlap in other tissues, we hypothesized that a similar situation exists in the uterus. Before this study, the presence of ADM peptide or receptors in the uterus had not been reported. To study the possible roles of ADM and CGRP in pregnancy, we measured peptide immunoreactivity and mRNA, and receptor binding and mRNA in nonpregnant and 20-day pregnant rat uteri. Here, we show the presence of ADM-IR and mRNA in the rat uterus, as well as specific ADM-binding sites. Studies of isolated rat uterine horns demonstrate that both ADM and CGRP attenuate the galanin-stimulated contraction of smooth muscle. This indicates a possible role for ADM in the control of uterine muscle tone.
Materials and Methods

Materials and animals
Rat ADM was obtained from Peptide Institute Inc. (Osaka, Japan). Human ADM, rat ␣CGRP, human ADM (22-52), and human ␣CGRP (8 -37) were synthesized using an Advanced Chemtech 396 MPS synthesizer (Advanced Chemtech Inc., Louisville, KY). All peptides were purified by HPLC and checked for correct molecular weight by mass spectroscopy. 
RIA
Tissue extraction. Whole uteri and placentae from Wistar rats (five nonpregnant, seven pregnant) were weighed and extracted for peptide immunoreactivity by plunging into 10 ml of 0.5 m acetic acid per gram of tissue and boiling for 10 min. Extracts were cooled on ice and frozen at Ϫ20 C until assay. Aliquots (100 l) of the extracts were dried by rotary evaporation, resuspended directly in the relevant assay buffer, and assayed in duplicate for ␣CGRP or rat ADM. Values are expressed as pmol/g wet weight tissue. The peptide contents of the nonpregnant and pregnant uteri were compared by Student's unpaired t test.
ADM RIA. RIA for rat ADM was performed, using an antiserum raised in rabbits against synthetic human ADM conjugated to BSA, using the glutaraldehyde method (33) . The antiserum (designated FC1) crossreacted fully with rat ADM and was used at a final dilution of 1:4,000. There was no cross-reactivity with synthetic rat ␣CGRP, IAPP, or calcitonin. Radioactive tracer was prepared from a synthetic ADM (22-52) fragment (15 g, 2.6 nmol) using the iodogen (1, 3, 4, 6-tetrachloro-3␣, 6␣-diphenylglycoluril) method, as previously described (34) . Iodinated peptide was separated by reversed-phase HPLC (Waters C 18 Novapak, Millipore, Milford, MA) using a linear gradient of 10 -40% aqueous acetonitrile containing 0.05% trifluoroacetic acid over 80 min. The specific activity of the tracer was 22.1 Bq/fmol. The assay was set up in a final vol of 0.7 ml [the assay buffer comprising 0.06 m sodium phosphate (pH 7.2), 10 mm EDTA, 7 mm sodium azide, containing 0.3% (wt/vol) BSA] and incubated at 4 C for 3 days. Bound and free tracer were separated by dextran-coated charcoal. The detection limit was 3.5 fmol/ tube at 95% confidence limits. The intra-and interassay coefficients of variation were 8% and 12.5%, respectively. CGRP RIA. RIA for ␣CGRP was as previously described (8). The detection limit was 1 fmol/tube at 95% confidence limits. The antiserum (CG7) (used at a final dilution of 1:112,000) cross-reacted fully with ␣CGRP, displayed 2% cross-reactivity with ␤CGRP, and did not crossreact with rat ADM or IAPP. The intra-and interassay coefficients of variation were 6.6% and 10.8%, respectively. Radioactive tracer was 125 I-[Tyr 0 ]␣CGRP (12 g; 2.4 nmol) iodinated using the iodogen method, as previously described (34) . Iodinated peptide was separated by reversed-phase HPLC using a linear gradient of 20 -50% aqueous acetonitrile containing 0.05% trifluoroacetic acid over 90 min. The specific activity of the tracer was 35.9 Bq/fmol.
Northern blot analysis
RNA preparation and Northern blotting. Nonpregnant and pregnant rats (n ϭ 8) were killed and the uteri removed and pooled in pairs (4 nonpregnant and 4 pregnant pairs). Placentae also were collected and pooled from pairs of pregnant animals. All tissues were frozen immediately in liquid nitrogen and stored at Ϫ80 C until extraction. Total RNA was prepared from frozen tissues using the acid guanidinium thiocyanate/phenol/chloroform method (35) . Total RNA (50 g) was fractionated, using denaturing MOPS/formaldehyde/1% agarose gels, and transferred to Hybond-N (Amersham International) nylon membranes, followed by baking at 80 C for 2 h. cDNA probes. Membranes were probed for rat ADM mRNA using a 150-bp cDNA probe corresponding to the entire coding sequence of rat ADM (bases 283-432) (2). The probe was labeled using a specific antisense primer corresponding to nucleotides 412-432 of the rat ADM cDNA sequence. The probe for rat ␣CGRP represents the 3Ј noncoding sequence of the corresponding cDNA, as previously described (29) . Membranes were probed for rat ADM receptor mRNA using a 416-bp cDNA probe corresponding to nucleotides 467-882 of the coding region. The fragment used was generated by BglI digestion of a 1.2-kb cloned fragment (22) . The probe for the CGRP 1 receptor was approximately 700 bp, prepared from the rat homologue (Clark, Adrian J. L., manuscript in preparation) of the dog RDC1 CGRP 1 receptor cDNA. The sequence of the rat CGRP 1 receptor probe corresponded to bases 293-1040 of the dog CGRP 1 receptor (23). The ␣CGRP and both receptor probes were labeled by random hexanucleotide priming (36) . All probes were labeled with [␣-
32 P]-dCTP to a specific activity more than 7 ϫ 10 8 dpm/g.
Hybridization and quantification.
The prehybridization, hybridization, and washing conditions were as previously described (37) . Membranes were probed for either peptide precursor mRNA or receptor mRNA. After probing for the first mRNA, membranes were stripped of radioactive probe by incubation in 1 ϫ TE (10 mm Tris/HCl, pH 7.5, containing 1 mm EDTA, pH 8.0) containing 0.5% (wt/vol) SDS for 15 min at 80 C. Stripped membranes then were probed for the second mRNA to be analyzed. Washed membranes were exposed to Kodak XAR-5 film (IBI Ltd, Cambridge, UK) at Ϫ70 C, then counted using a phosphorimager (PhosphorImager SF, Molecular Dynamics Ltd., Chesham, Buckinghamshire, UK). Signals were normalized for RNA loading by reprobing with labeled oligo(dT), as previously described (38) . Results are expressed as the ratio of the counts obtained with the probe of interest divided by the counts obtained with oligo(dT). The relative abundances of mRNA in nonpregnant and pregnant uteri were compared by students unpaired t test.
Receptor-binding assays
Membrane preparation. Uteri from nonpregnant and pregnant (20-day gestation) Wistar rats were frozen in liquid nitrogen. Membranes were prepared by differential centrifugation, as previously described (34).
Briefly, tissue was homogenized in ice-cold HEPES (50 mm) buffer (pH 7.6) containing sucrose (0.25 m), soybean trypsin inhibitor (10 g/ml), pepstatin (0.5 g/ml), leupeptin (0.5 g/ml), antipain (0.5 g/ml), benzamidine (0.1 g/ml), aprotinin (30 g/ml), and bacitracin (0.1 mg/ml). The homogenates were centrifuged at 1,500 ϫ g for 10 min at 4 C and the supernatants centrifuged at 100,000 ϫ g for 1 h at 4 C. The pellets were resuspended in homogenization buffer without sucrose and centrifuged at 100,000 ϫ g at 4 C for 1 h. The membranes were resuspended, as above, to a final concentration of approximately 4 mg protein/ml and stored at Ϫ80 C.
Peptide iodination. [Tyr 0 ]␣CGRP (12 g; 2.4 nmol) was iodinated by the iodogen method, as described in the CGRP RIA protocol. Rat ADM also was iodinated by the iodogen method (20) . Briefly, 12.5 g (2 nmol) of rat ADM in 10 l of 0.2 m phosphate buffer (pH 7.2) were reacted with 10 g iodogen and 37 MBq Na 125 I for 4 min at 22 C. The 125 I-peptide was purified by reversed-phase HPLC, as detailed for CGRP. Fractions showing binding (specific activity ϭ 10.4 Bq/fmol) were aliquoted, freeze-dried, and stored at Ϫ80 C. ) 125 I-rat ADM, as previously described (20) . Nonspecific binding was determined in the presence of 1 m unlabeled rat ADM. The binding site-125 I-ADM complex was separated from free tracer, as above.
Equilibrium competition curves were constructed in the presence of constant amounts of membrane protein and radiolabeled peptide with the concentration of the unlabeled peptide varied from 0 -1 m. Binding data were analyzed by nonlinear regression to determine the dissociation constant (K D ) or absolute inhibition constant and number of binding sites (B max ), using the Receptor-Fit program (Lundon Software, Cleveland, OH). Statistical analysis of one-site vs. two-site fits for competition curves were performed within the program by F test. Only P values less than 0.05 were considered to be significant.
Isolated rat uteri
The organ bath protocol used has previously been described (39) . Nonpregnant rat uteri were mounted in 10-ml organ baths containing modified Krebs solution (115 mm NaCl, 1.2 mm KH 2 PO 4 , 4.7 mm KCl, 1.2 mm MgSO 4 .7H 2 O, 25 mm NaHCO 3 , 5.5 mm glucose, and 1.6 mm CaCl 2 ) at 30 C and pH 7.4, aerated with a mixture of oxygen and carbon dioxide (95:5%). Recordings were made using a T3 isotonic transducer and a Washington 400MD4C four-channel recorder (Palmer Bioscience, Kent, UK). The preparations were equilibrated under a resting tension of 0.5 g for a 45-min period to achieve a steady baseline. Tissues were allowed a 20-min recovery period after each peptide addition. The uteri were initially tested for their contractile response by injection of 0.1 m porcine galanin directly into the organ bath. For all subsequent analyses, the magnitudes of responses were measured for 3 min after addition of galanin. A second galanin response was performed to determine whether a similar control response was observed. After recovery, either rat ␣CGRP (0.1 m) or human ADM (5 m) were applied to the tissues, followed 1 min later by addition of galanin (0.1 m). After washing and recovery, tissues were treated for a third time with 0.1 m porcine galanin to ensure that a contractile response still occurred. This protocol was performed on six separate uteri for each peptide. In a separate group of uteri, the effect of addition of ␣CGRP (8 -37) before addition of CGRP or ADM was assessed. The tissues were exposed twice to galanin, as detailed above. After recovery, ␣CGRP (8 -37) (2 m) was applied, followed 1 min later by either rat ␣CGRP (0.1 m) or human ADM (5 m) and followed 1 min later by addition of galanin (0.1 m). After washing and recovery, tissues were treated for a third time with 0.1 m porcine galanin to ensure that a contractile response still occurred. This protocol was performed on six separate uteri for each peptide. Statistical comparison of the responses to ADM and CGRP was performed by students unpaired t test.
Results
ADM and ␣CGRP immunoreactivity
ADM-IR was detected in nonpregnant and pregnant rat uteri (Table 1 ). No significant difference was detected between the levels of ADM-IR in nonpregnant and pregnant uteri. ␣CGRP-IR was detected in the nonpregnant uterus at a level approximately 5-fold greater than the ADM content. ␣CGRP-IR could not be detected in the pregnant uteri. No immunoreactivity for either peptide was found in rat placental extracts.
ADM and ␣CGRP mRNA ADM mRNA was detected in both the nonpregnant and pregnant uteri, placentae, and lung but not liver (Fig. 1) . The band was approximately 1.6 kb in size, as expected (2). After correction for differences in RNA loading by oligo(dT) hybridization, the ratio of the signals, with nonpregnant uterus arbitrarily normalized to 1.0, are (values are mean Ϯ sem): lung 0.6, nonpregnant uterus 1.0 Ϯ 0.1, placenta 1.2 Ϯ 0.2, and pregnant uterus 1.8 Ϯ 0.3 [pregnant uterus vs. nonpregnant (n ϭ 4 for each), P Ͻ 0.05]. Before oligo(dT) normalization, the blot was stripped and reprobed for ␣CGRP mRNA. No signal was detected in any of these tissues after 7 days exposure, although brain stem total RNA probed at the same time produced a strong hybridizing band (results not shown).
ADM and CGRP receptor mRNA
A duplicate blot was probed for ADM receptor mRNA. Bands of the expected 1.8-, 3.0-, and 5.0-kb size (Fig. 2, a-c ) (22) were seen in the placenta, liver, and lung, with no bands visible in uterine total RNA from either nonpregnant or pregnant rats (Fig. 2) . The blot was stripped and reprobed for CGRP 1 receptor mRNA. Signals were observed hybridizing to a band of the expected size of 2.2 kb in the placenta and both uterine states (Fig. 3) (23) . A band also was observed in lung but not in liver mRNA. After correction for differences in RNA loading by oligo(dT) hybridization, the ratio of the 
Competition of 125 I-ADM binding
Specific binding of 125 I-ADM in nonpregnant rat uterus represented 58.7 Ϯ 1.2% (n ϭ 3) of the total radioactivity bound. Rat ADM, but not rat ␣CGRP or ␣CGRP (8 -37), competed for 125 I-ADM binding in uterine membranes (Fig.  4) . The K D of the binding site for ADM was 80 Ϯ 6 pm and the B max was 21 Ϯ 2 fmol/mg membrane protein (n ϭ 3). Specific binding sites for ADM also were characterized in membranes from pregnant uteri, with respect to competition for 125 I-ADM by rat ADM. The K D of the binding site for rat ADM in these tissues was 160 Ϯ 20 pm, and the B max was 211 Ϯ 39 fmol/mg membrane protein (n ϭ 3). Thus, the density of ADM-binding sites was 10-fold greater in pregnant uteri, compared with nonpregnant uteri (P Ͻ 0.01).
Competition of 125 I-CGRP binding
Specific binding of 125 I-CGRP in nonpregnant rat uterus represented 87.0 Ϯ 1.6% of the total radioactivity bound. Unlabeled rat ␣CGRP, ␣CGRP (8 -37) , and rat ADM competed for the 125 I-CGRP-binding sites with the following order of potency: rat CGRP more than rat ADM more than ␣CGRP (8 -37) (Fig. 5) 270 pm, respectively. CGRP-binding sites also were analyzed in membranes from pregnant uteri. The K D of the binding site for rat ␣CGRP in membranes from pregnant uterus was 530 Ϯ 190 pm, and the B max was 153 Ϯ 5 fmol/mg membrane protein (n ϭ 3). There was no significant difference between the B max values for CGRP-binding sites in nonpregnant and pregnant uteri.
Nonlinear regression analysis of the competition curves as one-or two-site fit models revealed both CGRP and ADM binding to be best explained by single sites.
Isolated rat uteri
Treatment of nonpregnant uteri with 0.1 m galanin (n ϭ 12) stimulated uterine contraction, as expected (27) , and this response was normalized (100%). The subsequent effects of rat ␣CGRP and human ADM upon galanin-stimulated contraction were expressed as a percentage of the control response. Addition of rat ␣CGRP (0.1 m) or human ADM (5 m) to the incubation chamber 1 min before the addition of galanin (0.1 m) significantly reduced the magnitude of the agonist-stimulated contraction. The reductions of the contractile response observed were 77 Ϯ 10% (n ϭ 6) and 57 Ϯ 10% (n ϭ 6) for rat ␣CGRP and human ADM, respectively. A typical tracing of the galanin (control) response and the subsequent effect of rat ␣CGRP/human ADM on galaninstimulated uterine contraction is shown in Fig. 6 . A lower dose of human ADM (1 m) had little effect upon galaninstimulated contraction (data not shown). After washing off the peptides and allowing the tissue to recover, the final addition of galanin elicited contractile responses of 60 Ϯ 13% (after CGRP) and 74 Ϯ 8% (after ADM) of the magnitude of the first addition. ␣CGRP (8 -37), administered before the addition of CGRP or ADM, resulted in contractile responses to the subsequent galanin addition of 143 Ϯ 20% and 126 Ϯ 16% of the control response to galanin.
Discussion
ADM-IR or mRNA have not previously been characterized in the uterus. We show that immunoreactive ADM is present in the nonpregnant uterus at relatively low levels (0.68 Ϯ 0.08 pmol/g wet weight tissue), approximately 5%, 5.6%, and 7.4% of the contents previously reported for the lung, adrenal gland, and cardiac atrium, respectively (3). ␣CGRP-IR in the nonpregnant uterus, similar to that previously reported by this laboratory (7), is approximately 5-fold greater than the ADM content. No CGRP-IR was observed in the pregnant rat uterus. This absence of CGRP-IR is consistent with the neuronal degeneration previously reported in guinea pigs during late pregnancy (28) . Thus, it is unlikely that CGRP has a role in the control of uterine vascular or nonvascular smooth muscle activity in late pregnancy or at parturition.
In contrast to the peptide content, the abundance of ADM mRNA in nonpregnant uterus is greater (170%) than in the lung. The levels of mRNA in the pregnant rat uterus are 1.8-fold greater than in nonpregnant uterus (P Ͻ 0.05, students unpaired t test). The lung contains high levels of ADM mRNA, second only to the adrenal gland, in rat tissues. Thus, the uterus may be a previously undetected major source of ADM. The discrepancy between the magnitude of the differences in peptide and mRNA contents is consistent with the concept that ADM is constitutively released by most tissues (40, 41) . Thus, in late pregnancy, in the rat, the difference between the ADM-IR and ADM mRNA contents, when compared with those in the nonpregnant uterus, may indicate that greater amounts of ADM are being synthesized and released by the pregnant uterus. This correlates to a reported increase in plasma ADM in humans during pregnancy (42) . If this is the case, up-regulation of ADM synthesis and release suggests that ADM may play a role in the control of uterine vascular or nonvascular smooth muscle tone in late pregnancy. The control of muscle tone by ADM could compensate for the loss of CGRP in late pregnancy caused by neuronal degeneration (28) . No ␣CGRP mRNA was observed in the nonpregnant or pregnant rat uterus. In the rat, ␣CGRP mRNA previously has been identified in the dorsal root ganglia and spinal motoneurones (29, 30) . The peptide is synthesized in the cell bodies of these neurones and transported to their terminals located within tissues (43) . The absence of detectable ␣CGRP mRNA in the uterus is consistent with this observation. Although ADM mRNA is present in the placenta, again no mRNA was observed for ␣CGRP. The inability to detect immunoreactivity for either peptide in placenta could indicate that ␣CGRP is not produced by this tissue and ADM is produced but released extremely rapidly.
We have identified the presence of specific and pharmacologically distinct binding sites for ADM and CGRP in the rat uterus. The ADM-binding sites display a high affinity for rat ADM, with little competition by rat ␣CGRP or ␣CGRP (8 -37) . This binding profile matches that observed in the rat ADM receptors previously characterized in our laboratory (20) . The affinity of these binding sites is similar to the specific binding sites in the heart. The density of ADM-binding sites was approximately 10-fold greater in the pregnant uterus, compared with the nonpregnant uterus, indicating an extensive up-regulation of this receptor. The detection of mRNA for the ADM receptor in placenta, but not in the uterus, corresponds to previously published data for poly-A ϩ RNA (22, 44) . The presence of specific ADM-binding sites, but no mRNA signal for the cloned ADM receptor in the uterus in either state, indicates a possible ADM receptor heterogeneity, as suggested by Zimmerman et al. (45) .
The CGRP-binding sites showed competition in the order of potency: rat ␣CGRP more than rat ADM more than ␣CGRP (8 -37). There was no significant difference between the number of CGRP-binding sites or the abundance of CGRP 1 receptor mRNA in pregnant uterus compared with nonpregnant tissue. There was an abundance of CGRP 1 receptor mRNA in the placenta. Recently, we have identified the orphan dog RDC1 receptor as a CGRP 1 receptor, but distribution studies of this receptor did not include the uterus (23, 46) . The presence of a CGRP receptor in human placenta with a greater affinity for ␤CGRP than ␣CGRP has previously been reported (47) . A CGRP receptor with pharmacological characteristics of a CGRP 1 receptor recently has been identified in human synovial tissue (48) . This receptor is not present in the placenta. However, the human receptor is more closely related to the calcitonin receptors than the ADM receptor and shares little sequence homology with RDC1 (49) .
As a preliminary step in the identification of a role for ADM in the uterus, we have tested the inhibitory effects of both human ADM and ␣CGRP upon the contractile response of uterine muscle to galanin. At the same molar concentration of galanin and CGRP as were used for this study, ␣CGRP previously has been reported to inhibit the galanin-induced contraction of uterine smooth muscle by 93% (27) . We also obtained a powerful relaxation by CGRP (77%). ADM also inhibited galanin-induced contractions but was less effective than CGRP. We also have shown that the effects of both CGRP and ADM are abolished by pretreatment of rat uterine tissue with CGRP (8 -37) , suggesting that the contractile effects of both peptides are mediated by CGRP 1 receptors. Hence, the role of the specific ADM receptors identified in the uterus remains uncertain.
We have shown, for the first time, the presence of ADM peptide and specific binding sites in the rat uterus. The data presented regarding the presence of both ADM and ␣CGRP peptide and receptors in the uterus indicate that both may have a role in uterine function. In addition, the content and mRNA of both the peptides and their receptors differ during the late gestation phase, in comparison with uteri from nonpregnant rats. CGRP previously has been shown to elicit dose-dependent relaxation of uterine smooth muscle (24, 27) . ADM may have a similar relaxant role in the uterus, particularly late in pregnancy, when ADM mRNA is increased and CGRP levels are undetectable. A role for ADM in control of uterine vascular tone cannot be excluded, even if the effect of ADM upon uterine smooth muscle is via CGRP 1 receptors.
However, the effect mediated by the specific ADM receptors has yet to be established.
